Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC (CAT#: ADC-036LCT)
This ADC product is composed of an anti-CD22 antibody (Inotuzumab) conjuagated via a hydrazone linker to Calicheamicin (Inotuzumab-hydrazone-Calicheamicin). It has demonstrated a response in Acute Lymphoblastic Leukemia, non-Hodgkin's lymphoma, Haematological
malignancies treatment by a MOA (Mechanism of Action) of Calicheamicins target DNA and cause strand scission. Calicheamicins bind with DNA in the minor groove.
Specific Inquiry
Normal Tissue
RNA Expression
Figure 1 Lymph node
(Germinal center cells
Staining: Medium
Intensity: Moderate
Quantity: 75%-25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/2418/6101_A_7_8.jpg
(Germinal center cells
Staining: Medium
Intensity: Moderate
Quantity: 75%-25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/2418/6101_A_7_8.jpg
Figure 2 Spleen
(Cells in red pulp
Staining: Medium
Intensity: Strong
Quantity: <25%
Location: Cytoplasmic/membranous
Cells in white pulp
Staining: High
Intensity: Strong
Quantity: 75%-25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/2418/6101_B_7_4.jpg
(Cells in red pulp
Staining: Medium
Intensity: Strong
Quantity: <25%
Location: Cytoplasmic/membranous
Cells in white pulp
Staining: High
Intensity: Strong
Quantity: 75%-25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/2418/6101_B_7_4.jpg
Figure 3 RNA cell line category: Cell line enhanced (Daudi, REH, U-698, WM-115)
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000012124-CD22
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000012124-CD22
Figure 3 RNA cell line category: Cell line enhanced (Daudi, REH, U-698, WM-115)
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000012124-CD22
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000012124-CD22
Specifications
- Antibody Overview
- Humanized monoclonal Antibody (Anti-CD22)
- Clone
- Inotuzumab
- Linker
- hydrazone
- Linker Class/Description
- Acid-labile linkers, belonging to chemically cleavable linkers, are designed based on a pH-dependent release mechanism and remain intact during systemic circulation in the blood's neutral pH environment (pH 7.3-7.5) but to undergo hydrolysis and release drug once the ADC is internalized into mildly acidic endosomal (pH 5.0-6.5) and lysosomal (pH 4.5-5.0) compartments of the cell.
- Drug
- Calicheamicin
- Drug Class/Description
- Calicheamicin, produced by prokaryotic microorganisms, are a group of DNA cleaving agents with similar structure that binds in the minor grove of DNA in a relatively sequence-specific manner.
Target
- Introduction
- CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases.
CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer's patches in mice.
- Alternative Names
- CD22; CD22 molecule; SIGLEC2; SIGLEC-2; B-cell receptor CD22; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2;
- Gene ID
- 933
- UniProt ID
- P20273
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone Inotuzumab"
See other products for "CD22"
Select a product category from the dropdown menu below to view related products.
Please select product type
scFv Fragment Antibody
Mouse Antibody
Immunotoxin
Chimeric Antibody
Humanized Antibody
Human Antibody
Fab Glycosylation
Fc Glycosylation
Recombinant Antibody
Blocking Antibody
Rabbit Monoclonal Antibody
Fab Fragment Antibody
ADCC Enhanced Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-1248z-S(P) | Recombinant Anti-Human CD22 Antibody scFv Fragment | ELISA, WB, IF, FuncS | scFv |
| HPAB-0249-FY-S(P) | Recombinant Human Anti-CD22 Antibody scFv Fragment | F | Human scFv |
| HPAB-0709-FY-F(E) | Mouse Anti-CD22 Recombinant Antibody (clone AB008); scFv Fragment | ELISA | Mouse scFv |
| HPAB-0370-FY-S(P) | Human Anti-CD22 Recombinant Antibody; scFv Fragment (HPAB-0370-FY-S(P)) | ELISA | Humanized scFv |
| HPAB-2052-FY-S(P) | Human Anti-CD22 Recombinant Antibody (clone B28); scFv Fragment | FC | Human scFv |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for ADC-036LCT. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: WB, FC, IP, ELISA, Neut, FuncS, IF
Application: IF, IP, Neut, FuncS, ELISA, FC, WB
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: FC, IP, ELISA, Neut, FuncS, IF, WB
-1.png)
Application: ELISA, FC, Block, SPR
Application: Neut, FC, IHC-Fr, IP, BA
Application: ELISA, IHC, FC, IP, IF, FuncS
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
